Close
  Indian J Med Microbiol
 

Figure 3: Overall survival curves of PSA responders and nonresponders. (a) Overall survival rate after CRPC in patients with PSA responders and nonresponders to AW. PSA responders to AW therapy had significantly longer survival than nonresponders (P = 0.011). (b) Overall survival rate after CRPC in patients with PSA responders and nonresponders to AA therapy. PSA responders to AA therapies had significantly longer survival than nonresponders (P < 0.001). AA: alternative antiandrogen; AW: antiandrogen withdrawal; CRPC: castration-resistant prostate cancer; PSA: prostate-specific antigen.

Figure 3: Overall survival curves of PSA responders and nonresponders. (<b>a</b>) Overall survival rate after CRPC in patients with PSA responders and nonresponders to AW. PSA responders to AW therapy had significantly longer survival than nonresponders (<i>P</i> = 0.011). (<b>b</b>) Overall survival rate after CRPC in patients with PSA responders and nonresponders to AA therapy. PSA responders to AA therapies had significantly longer survival than nonresponders (<i>P</i> < 0.001). AA: alternative antiandrogen; AW: antiandrogen withdrawal; CRPC: castration-resistant prostate cancer; PSA: prostate-specific antigen.